Buparlisib
As of the edition of 20 October 2026, Buparlisib is a small molecule: stopped in 2023; acts on PIK3CA, PIK3CB and PIK3CD and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 87, 22 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Blood and lymph; Digestive system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 10 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Buparlisib.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product10 company-target rows are on route A because of Buparlisib.
See the 10 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PIK3CD | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | O00329 |
| PIK3CA | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | P42336 |
| PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | P42338 |
| PIK3CG | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | P48736 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 45 | 37 | 0 | 8 |
| Phase 2 | 39 | 23 | 0 | 13 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 87 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2008 to now |
| Pfizer | Lead sponsor of trials | 2011 to now |
| SCRI Development Innovations | Lead sponsor of trials | 2011 to now |
| US Oncology | Lead sponsor of trials | 2014 to now |
| Adlai Nortye Biopharma | Lead sponsor of trials | 2021 to now |